BioSpace

The race for access: How the FAIR Act could reclaim U.S. biotech leadership

In this episode of Denatured, you’ll hear from Max Bronstein, CEO of Aviva Strategies and Teresa Barnes, Chief Executive Warrior of PF Warriors. We dig into why U.S. patients are losing access to rare disease trials happening abroad and how the FAIR Act’s accelerated, harmonized reviews could help the U.S. keep pace while getting lifesaving studies to patients faster.

By BioSpace

1 min read
The race for access: How the FAIR Act could reclaim U.S. biotech leadership
The race for access: How the FAIR Act could reclaim U.S. biotech leadership

Got news to share with the events industry?

Submit a press release or story tip and reach thousands of event professionals.

Get in touch→

More in Health Tech

Related Insights